Targeting proliferating cell nuclear antigen enhances ionizing radiation-induced cytotoxicity in prostate cancer cells.
androgen receptor signaling
castration resistant prostate cancer
proliferating cell nuclear antigen
proliferating cell nuclear antigen inhibitors
radiosensitization
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
revised:
30
07
2024
received:
13
03
2024
accepted:
19
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
Proliferating cell nuclear antigen (PCNA) is essential for DNA replication and repair, cell growth, and survival. PCNA also enhances androgen receptor (AR) signaling in prostate cancer (PC) cells. We identified a PCNA interaction protein (PIP) box at the N-terminal domain of AR and developed a small peptide PCNA inhibitor R9-AR-PIP containing AR PIP-box. We also identified a series of small molecule PCNA inhibitors (PCNA-Is) that bind directly to PCNA and interrupt PCNA functions. The present study investigated the effects of the PCNA inhibitors on the sensitivity of PC cells to X-ray radiation. The effects of targeting PCNA on radio sensitivity of PC cells were investigated in four lines of castration-resistant PC (CRPC) cells with different AR expression statuses. The cells were treated with the PCNA inhibitors and X-ray radiation alone or in combination. The effects of the treatment on expression of AR target genes, DNA damage response, DNA damage, homologous recombination repair (HRR), and cytotoxicity were evaluated. We found that the androgen response element (ARE) occupancy of the DNA damage response gene PARP1 by AR is significantly attenuated by PCNA-I1S or R9-AR-PIP combined with X-ray radiation, while X-ray radiation alone does not enhance the ARE occupancy. PCNA-I1S or R9-AR-PIP alone significantly inhibits occupancy of the AR-occupied regions (AROR) in PRKDC and XRCC2 genes. R9-AR-PIP and PCNA-I1S inhibit expression of AR-Vs target gene cyclin A2 and show the additive effects with radiation in AR-positive CRPC cells. Targeting PCNA by PCNA-I1S and R9-AR-PIP downregulates expression of DNA damage response genes EXO1, Rad54L, Rad51, and/or PARP1 and shows the additive effects with radiation as compared with their respective controls in AR-positive CRPC LNCaP-AI, 22Rv1, and R1-D567 cells, but not in AR-negative PC-3 cells. R9-AR-PIP and PCNA-I1S elevate the levels of phospho-DNA-PKcs(S These data provide a strong rationale for the therapy studies using PCNA-I1S or R9-AR-PIP in combination with X-ray radiation against CRPC tumors in preclinical models.
Sections du résumé
BACKGROUND
BACKGROUND
Proliferating cell nuclear antigen (PCNA) is essential for DNA replication and repair, cell growth, and survival. PCNA also enhances androgen receptor (AR) signaling in prostate cancer (PC) cells. We identified a PCNA interaction protein (PIP) box at the N-terminal domain of AR and developed a small peptide PCNA inhibitor R9-AR-PIP containing AR PIP-box. We also identified a series of small molecule PCNA inhibitors (PCNA-Is) that bind directly to PCNA and interrupt PCNA functions. The present study investigated the effects of the PCNA inhibitors on the sensitivity of PC cells to X-ray radiation.
METHODS
METHODS
The effects of targeting PCNA on radio sensitivity of PC cells were investigated in four lines of castration-resistant PC (CRPC) cells with different AR expression statuses. The cells were treated with the PCNA inhibitors and X-ray radiation alone or in combination. The effects of the treatment on expression of AR target genes, DNA damage response, DNA damage, homologous recombination repair (HRR), and cytotoxicity were evaluated.
RESULTS
RESULTS
We found that the androgen response element (ARE) occupancy of the DNA damage response gene PARP1 by AR is significantly attenuated by PCNA-I1S or R9-AR-PIP combined with X-ray radiation, while X-ray radiation alone does not enhance the ARE occupancy. PCNA-I1S or R9-AR-PIP alone significantly inhibits occupancy of the AR-occupied regions (AROR) in PRKDC and XRCC2 genes. R9-AR-PIP and PCNA-I1S inhibit expression of AR-Vs target gene cyclin A2 and show the additive effects with radiation in AR-positive CRPC cells. Targeting PCNA by PCNA-I1S and R9-AR-PIP downregulates expression of DNA damage response genes EXO1, Rad54L, Rad51, and/or PARP1 and shows the additive effects with radiation as compared with their respective controls in AR-positive CRPC LNCaP-AI, 22Rv1, and R1-D567 cells, but not in AR-negative PC-3 cells. R9-AR-PIP and PCNA-I1S elevate the levels of phospho-DNA-PKcs(S
CONCLUSION
CONCLUSIONS
These data provide a strong rationale for the therapy studies using PCNA-I1S or R9-AR-PIP in combination with X-ray radiation against CRPC tumors in preclinical models.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The Department of Defense, Prostate Cancer Research Program (DOD-PCRP)
Informations de copyright
The Prostate© 2024 The Author(s). The Prostate published by Wiley Periodicals LLC.
Références
Chang AJ, Autio KA, Roach M, Scher HI. High‐risk prostate cancer classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308‐323. doi:10.1038/nrclinonc.2014.68
Naryzhny SN, Desouza LV, Siu KWM, Lee H. Characterization of the human proliferating cell nuclear antigen physico‐chemical properties: aspects of double trimer stability. Biochem Cell Biol. 2006;84(5):669‐676.
Almendral JM, Huebsch D, Blundell PA, Macdonald‐Bravo H, Bravo R. Cloning and sequence of the human nuclear protein cyclin: homology with DNA‐binding proteins. Proc Natl Acad Sci. 1987;84(6):1575‐1579.
Kim MS, Jeong EG, Ahn CH, Kim SS, Lee SH, Yoo NJ. Frameshift mutation of UVRAG, an autophagy‐related gene, in gastric carcinomas with microsatellite instability. Hum Pathol. 2008;39(7):1059‐1063. doi:10.1016/j.humpath.2007.11.013
Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014;35(4):178‐186. doi:10.1016/j.tips.2014.02.004
Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans. 2009;37(Pt 3):605‐613.
Naryzhny SN. Proliferating cell nuclear antigen: a proteomics view. Cell Mol Life Sci. 2008;65(23):3789‐3808.
Krishna TS, Kong XP, Gary S, Burgers PM, Kuriyan J. Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA. Cell. 1994;79(7):1233‐1243.
Gulbis JM, Kelman Z, Hurwitz J, O'Donnell M, Kuriyan J. Structure of the C‐terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell. 1996;87(2):297‐306.
Kelman Z, O'Donnell M. Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps. Nucleic Acids Res. 1995;23(18):3613‐3620.
Boehm EM, Washington MT. R.I.P. to the PIP: PCNA‐binding motif no longer considered specific: PIP motifs and other related sequences are not distinct entities and can bind multiple proteins involved in genome maintenance. BioEssays. 2016;38(11):1117‐1122. doi:10.1002/bies.201600116
Slade D. Maneuvers on PCNA rings during DNA replication and repair. Genes. 2018;9(8):416. doi:10.3390/genes9080416
Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007;129(4):665‐679.
Maga G, Hübscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci. 2003;116(Pt 15):3051‐3060.
Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res. 2007;13(19):5692‐5702. doi:10.1158/1078-0432.CCR-07-1078
Spires SE, Darrell Jennings C, Banks ER, Wood DP, Davey Jr. DD, Cibull ML. Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators. Urology. 1994;43(5):660‐666.
Naito S, Sakamoto N, Kotoh S, et al. Proliferating cell nuclear antigen in needle biopsy specimens of prostatic carcinoma. Eur Urol. 1994;26(2):164‐169.
Kallakury BV, Sheehan CE, Rhee SJ, et al. The prognostic significance of proliferation‐associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki‐67, proliferating cell nuclear antigen, and p34cdc2. Cancer. 1999;85(7):1569‐1576.
Harper ME, Glynne‐Jones E, Goddard L, et al. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate. 1992;20(3):243‐253.
Bantis A, Giannopoulos A, Gonidi M, et al. Expression of p120, Ki‐67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology. 2004;15(1):25‐31.
Mulligan JM, Mai KT, Parks W, Gerridzen RG. Proliferating cell nuclear antigen (PCNA) and MIB 1: markers of locally advanced and biologically aggressive prostate cancer. Can J Urol. 1997;4(3):422‐425.
Lu S, Dong Z. Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‐mediated signaling. Int J Oncol. 2021;59(1):41. doi:10.3892/ijo.2021.5221
Dillehay KL, Seibel WL, Zhao D, Lu S, Dong Z. Target validation and structure‐activity analysis of a series of novel PCNA inhibitors. Pharmacol Res Perspect. 2015;3(2):e00115. doi:10.1002/prp2.115
Dillehay KL, Lu S, Dong Z. Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer. Mol Cancer Ther. 2014;13(12):2817‐2826. doi:10.1158/1535-7163.MCT-14-0522
Tan Z, Wortman M, Dillehay KL, et al. Small‐molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth. Mol Pharmacol. 2012;81(6):811‐819. doi:10.1124/mol.112.077735
Lu S, Dong Z. Additive effects of a small molecular PCNA inhibitor PCNA‐I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells. PLoS One. 2019;14(10):e0223894. doi:10.1371/journal.pone.0223894
Tichy ED, Pillai R, Deng L, et al. Mouse embryonic stem cells, but not somatic cells, predominantly use homologous recombination to repair double‐strand DNA breaks. Stem Cells Dev. 2010;19(11):1699‐1711. doi:10.1089/scd.2010.0058
Goodwin JF, Schiewer MJ, Dean JL, et al. A hormone‐DNA repair circuit governs the response to genotoxic insult. Cancer Discovery. 2013;3(11):1254‐1271. doi:10.1158/2159-8290.CD-13-0108
Palomera‐Sanchez Z, Watson GW, Wong CP, et al. The phytochemical 3,3’‐diindolylmethane decreases expression of AR‐controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells. J Nutr Biochem. 2017;47:113‐119. doi:10.1016/j.jnutbio.2017.05.005
Lu S, Tsai SY, Tsai MJ. Molecular mechanisms of androgen‐independent growth of human prostate cancer LNCaP‐AI Cells1. Endocrinology. 1999;140:5054‐5059.
Ma CM, Coffey CW, DeWerd LA, et al. AAPM protocol for 40‐300 kV X‐ray beam dosimetry in radiotherapy and radiobiology. Med Phys. 2001;28(6):868‐893. doi:10.1118/1.1374247
Shibata Y, Nakamura T. Defective flap endonuclease 1 activity in mammalian cells is associated with impaired DNA repair and prolonged S phase delay. J Biol Chem. 2002;277(1):746‐754.
Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol. 2004;26(3):249‐261. doi:10.1385/MB:26:3:249
Gyori BM, Venkatachalam G, Thiagarajan PS, Hsu D, Clement MV. OpenComet: an automated tool for comet assay image analysis. Redox Biol. 2014;2:457‐465. doi:10.1016/j.redox.2013.12.020
Dong Z, Liu Y, Scott KF, et al. Secretory phospholipase A2‐IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis. 2010;31:1948‐1955.
Hörnberg E, Ylitalo EB, Crnalic S, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration‐resistance and short survival. PLoS One. 2011;6(4):e19059. doi:10.1371/journal.pone.0019059
Cao B, Qi Y, Zhang G, et al. Androgen receptor splice variants activating the full‐length receptor in mediating resistance to androgen‐directed therapy. Oncotarget. 2014;5(6):1646‐1656. doi:10.18632/oncotarget.1802
Xu D, Zhan Y, Qi Y, et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res. 2015;75(17):3663‐3671. doi:10.1158/0008-5472.CAN-15-0381
Polkinghorn WR, Parker JS, Lee MX, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discovery. 2013;3(11):1245‐1253. doi:10.1158/2159-8290.CD-13-0172
Kounatidou E, Nakjang S, McCracken SRC, et al. A novel CRISPR‐engineered prostate cancer cell line defines the AR‐V transcriptome and identifies PARP inhibitor sensitivities. Nucleic Acids Res. 2019;47(11):5634‐5647. doi:10.1093/nar/gkz286
Tarish FL, Schultz N, Tanoglidi A, et al. Castration radiosensitizes prostate cancer tissue by impairing DNA double‐strand break repair. Sci Transl Med. 2015;7(312):312. doi:10.1126/scitranslmed.aac5671
Wright TC, Dunne VL, Alshehri AHD, Redmond KM, Cole AJ, Prise KM. Abiraterone in vitro is superior to enzalutamide in response to ionizing radiation. Front Oncol. 2021;11:700543. doi:10.3389/fonc.2021.700543
Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374. doi:10.1038/s41467-017-00393-y
Le Dai J, Maiorino CA, Gkonos PJ, Burnstein KL. Androgenic up‐regulation of androgen receptor cDNA expression in androgen‐independent prostate cancer cells. Steroids. 1996;61(9):531‐539.
Manin M, Baron S, Goossens K, et al. Androgen receptor expression is regulated by the phosphoinositide 3‐kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J. 2002;366(Pt 3):729‐736. doi:10.1042/BJ20020585
Iyama T, Wilson DM. DNA repair mechanisms in dividing and non‐dividing cells. DNA Repair. 2013;12(8):620‐636. doi:10.1016/j.dnarep.2013.04.015
Meek K, Douglas P, Cui X, Ding Q, Lees‐Miller SP. Trans autophosphorylation at DNA‐dependent protein kinase's two major autophosphorylation site clusters facilitates end processing but not end joining. Mol Cell Biol. 2007;27(10):3881‐3890. doi:10.1128/MCB.02366-06
Spratt DE, Evans MJ, Davis BJ, et al. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Res. 2015;75(22):4688‐4696. doi:10.1158/0008-5472.CAN-15-0892
Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532‐2542. doi:10.1001/jama.2017.7248
Krause WC, Shafi AA, Nakka M, Weigel NL. Androgen receptor and its splice variant, AR‐V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol. 2014;54:49‐59. doi:10.1016/j.biocel.2014.06.013
Ciccarese C, Santoni M, Brunelli M, et al. AR‐V7 and prostate cancer: the watershed for treatment selection? Cancer Treat Rev. 2016;43:27‐35. doi:10.1016/j.ctrv.2015.12.003
Paschalis A, Sharp A, Welti JC, et al. Alternative splicing in prostate cancer. Nat Rev Clin Oncol. 2018;15(11):663‐675. doi:10.1038/s41571-018-0085-0
Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011;18(5):R183‐R196. doi:10.1530/ERC-11-0141
Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016;7(39):64447‐64470. doi:10.18632/oncotarget.10901
Lu J, der Steen TV, Tindall DJ. Are androgen receptor variants a substitute for the full‐length receptor? Nat Rev Urol. 2015;12(3):137‐144. doi:10.1038/nrurol.2015.13
Yu Z, Chen S, Sowalsky AG, et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014;20(6):1590‐1600. doi:10.1158/1078-0432.CCR-13-1863
Antonarakis ES, Lu C, Wang H, et al. AR‐V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028‐1038. doi:10.1056/NEJMoa1315815
Chen Z, Wu D, Thomas‐Ahner JM, et al. Diverse AR‐V7 cistromes in castration‐resistant prostate cancer are governed by HoxB13. Proc Natl Acad Sci. 2018;115(26):6810‐6815. doi:10.1073/pnas.1718811115
Yin Y, Li R, Xu K, et al. Androgen receptor variants mediate DNA repair after prostate cancer irradiation. Cancer Res. 2017;77(18):4745‐4754. doi:10.1158/0008-5472.CAN-17-0164
Liu G, Sprenger C, Wu PJ, et al. MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand. Oncotarget. 2015;6(1):288‐304. doi:10.18632/oncotarget.2672
Hu R, Dunn TA, Wei S, et al. Ligand‐independent androgen receptor variants derived from splicing of cryptic exons signify hormone‐refractory prostate cancer. Cancer Res. 2009;69(1):16‐22. doi:10.1158/0008-5472.CAN-08-2764
Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up‐regulated during prostate cancer progression and promotes androgen depletion‐resistant growth. Cancer Res. 2009;69(6):2305‐2313. doi:10.1158/0008-5472.CAN-08-3795
Sharp A, Coleman I, Yuan W, et al. Androgen receptor splice variant‐7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019;129(1):192‐208. doi:10.1172/JCI122819
Lu C, Brown LC, Antonarakis ES, Armstrong AJ, Luo J. Androgen receptor variant‐driven prostate cancer II: advances in laboratory investigations. Prostate Cancer Prostatic Dis. 2020;23(3):381‐397. doi:10.1038/s41391-020-0217-3
Honda M, Kimura T, Kamata Y, et al. Differential expression of androgen receptor variants in hormone‐sensitive prostate cancer xenografts, castration‐resistant sublines, and patient specimens according to the treatment sequence. Prostate. 2019;79(9):1043‐1052. doi:10.1002/pros.23816
Sun S, Sprenger CCT, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120(8):2715‐2730. doi:10.1172/JCI41824
Mudryj M, Tepper CG. On the origins of the androgen receptor low molecular weight species. Hormones and Cancer. 2013;4(5):259‐269. doi:10.1007/s12672-013-0152-z